Inhibitors of slit protein interactions with the heparan sulphate proteoglycan glypican-1: Potential agents for the treatment of spinal cord injury

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 4, 2010, Pages 417-421

  Lau, Elizabeth ^a   Margolis, Richard U ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Axonal regeneration; Glypican 1; Heparan sulphate; PI 88; Proteoglycans; Slit proteins; Spinal cord injury; Sulphated dextrans

Indexed keywords

DALTEPARIN; DEXTRAN SULFATE; ENOXAPARIN; FONDAPARINUX; GL 522 Y 1; GLYPICAN 1; HEPARIN DERIVATIVE; HEXAPOTASSIUM; PERIODATE; PHENOL DERIVATIVE; PI 88; SLIT PROTEIN; SR 122429A; SR 80027A; SR 80028A; SR 80037A; SR 80239A; SR 80258A; SR 80343A; SR 80403A; SR 80426A; SR 80488A; SR 80536A; SURAMIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NERVE FIBER REGENERATION; OXIDATION; PROTEIN PROTEIN INTERACTION; SPINAL CORD INJURY;

ANTICOAGULANTS; DALTEPARIN; DEXTRAN SULFATE; DRUG DESIGN; ENOXAPARIN; GLYCOPROTEINS; GLYPICANS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; NERVE TISSUE PROTEINS; OLIGOSACCHARIDES; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; PERIODIC ACID; POLYSACCHARIDES; PROTEIN BINDING; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; SPINAL CORD INJURIES;

EID: 77949877103     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05318.x     Document Type: Article

References (35)

1. Chédotal A. Slits and their receptors. Adv. Exp. Med. Biol. 2007 621 : 65 80.
2. Hou ST, Jiang SX, Smith RA. Permissive and repulsive cues and signaling pathways of axonal outgrowth and regeneration. Int. Rev. Cell Mol. Biol. 2008 267 : 125 181.
3. Killeen MT, Sybingco SS. Netrin, Slit and Wnt receptors allow axons to choose the axis of migration. Dev. Biol. 2008 323 : 143 151.
4. Liang Y, Annan RS, Carr SA et al. Mammalian homologues of the Drosophila Slit protein are ligands of the heparan sulfate proteoglycan glypican-1 in brain. J. Biol. Chem. 1999 274 : 17885 17892.
5. Ronca F, Andersen JS, Paech V, Margolis RU. Characterization of Slit protein interactions with glypican-1. J. Biol. Chem. 2001 276 : 29141 29147.
6. Zhang F, Ronca F, Linhardt RJ, Margolis RU. Structural determinants of heparan sulfate interactions with Slit proteins. Biochem. Biophys. Res. Commun. 2004 317 : 352 357.
7. Karthikeyan L, Flad M, Engel M, Meyer-Puttlitz B, Margolis RU, Margolis RK. Immunocytochemical and in situ hybridization studies of the heparan sulfate proteoglycan, glypican, in nervous tissue. J. Cell Sci. 1994 107 : 3213 3222.
8. Hu H. Cell-surface heparan sulfate is involved in the repulsive guidance activities of Slit2 protein. Nat. Neurosci. 2001 4 : 695 701.
9. Johnson KG, Ghose A, Epstein E, Lincecum J, O'Connor MB, Van Vactor D. Axonal heparan sulfate proteoglycans regulate the distribution and efficiency of the repellent slit during midline axon guidance. Curr. Biol. 2004 14 : 499 504.
10. Hussain SA, Piper M, Fukuhara N et al. A molecular mechanism for the heparan sulfate dependence of slit-robo signaling. J. Biol. Chem. 2006 281 : 39693 39698.
11. de Wit J, Verhaagen J. Proteoglycans as modulators of axon guidance cue function. Adv. Exp. Med. Biol. 2007 600 : 73 89.
12. Hagino S, Iseki K, Mori T et al. Slit and glypican-1 mRNAs are coexpressed in the reactive astrocytes of the injured adult brain. Glia 2003 42 : 130 138.
13. Hagino S, Iseki K, Mori T et al. Expression pattern of glypican-1 mRNA after brain injury in mice. Neurosci. Lett. 2003 349 : 29 32.
14. Wehrle R, Camand E, Chedotal A, Sotelo C, Dusart I. Expression of netrin-1, slit-1 and slit-3 but not of slit-2 after cerebellar and spinal cord lesions. Eur. J. Neurosci. 2005 22 : 2134 2144.
15. Bloechlinger S, Karchewski LA, Woolf CJ. Dynamic changes in glypican-1 expression in dorsal root ganglion neurons after peripheral and central axonal injury. Eur. J. Neurosci. 2004 19 : 1119 1132.
16. Liang Y, Häring M, Roughley P, Margolis RK, Margolis RU. Glypican and biglycan in the nuclei of neurons and glioma cells: Presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle. J. Cell Biol. 1997 139 : 851 864.
17. Cafferty WBJ, McGee AW, Strittmatter SM. Axonal growth therapeutics: Regeneration or sprouting or plasticity? Trends Neurosci. 2008 31 : 215 220.
18. Mousa SA, Feng X, Xie J et al. Synthetic oligosaccharide stimulates and stabilizes angiogenesis: Structure-function relationships and potential mechanisms. J. Cardiovasc. Pharmacol. 2006 48 : 6 13.
19. Gowda DC, Goossen B, Margolis RK, Margolis RU. Chondroitin sulfate and heparan sulfate proteoglycans of PC12 pheochromocytoma cells. J. Biol. Chem. 1989 264 : 11436 11443.
20. Ba-Charvet KTN, Brose K, Ma L et al. Diversity and specificity of actions of Slit2 proteolytic fragments in axon guidance. J. Neurosci. 2001 21 : 4281 4289.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976 72 : 248 254.
22. Lormeau J-C, Choa J, Petitou M, inventors. Sanofi SA, assignee. Low molecular weight heparins, with regular structure, preparation thereof and biological application thereof. US patent no. 4990502. 22 March 1994.
23. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: A novel inhibitor of angiogenesis. Expert Opin. Invest. Drugs 2008 17 : 1769 1776.
24. Yu G, Gunay NS, Linhardt RJ et al. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur. J. Med. Chem. 2002 37 : 783 791.
25. V-sulfated mannopentasaccharide analogue related to PI-88. Carbohydr. Res. 2004 339 : 1155 1162.
26. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. Cell. Physiol. 1992 150 : 194 203.
27. Ledoux D, Merciris D, Barritault D, Caruelle JP. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett. 2003 537 : 23 9.
28. Ledoux D, Papy-Garcia D, Escartin Q et al. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J. Biol. Chem. 2000 275 : 29383 29390.
29. Ma Q, Dudas B, Daud A et al. Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. Thromb. Res. 2002 105 : 303 309.
30. Pinhal MA, Trindade ES, Fareed J, Dietrich CP, Nader HB. Heparin and a cyclic octaphenol-octasulfonic acid (GL-522-Y-1) bind with high affinity to a 47-kDa protein from vascular endothelial cell surface and stimulate the synthesis and structural changes of heparan sulfate proteoglycan. Thromb. Res. 2001 103 : 35 45.
31. Ishida K, Wierzba MK, Teruya T, Simizu S, Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem. Biol. 2004 11 : 367 377.
32. Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC. Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother. Pharmacol. 1998 41 : 117 124.
33. Benezra M, Ishai-Michaeli R, Ben-Sasson SA, Vlodavsky I. Structure-activity relationships of heparin-mimicking compounds in induction of bFGF release from extracellular matrix and inhibition of smooth muscle cell proliferation and heparanase activity. J. Cell. Physiol. 2002 192 : 276 285.
34. Jimenez Hamann MC, Tsai EC, Tator CH, Shoichet MS. Novel intrathecal delivery system for treatment of spinal cord injury. Exp. Neurol. 2003 182 : 300 309.
35. Lin L, Rao Y, Isacson O. Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons. Mol. Cell. Neurosci. 2005 28 : 547 555.